Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Net Cash Flow (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Net Cash Flow readings, the most recent being -$9.3 million for Q4 2022.

  • On a quarterly basis, Net Cash Flow fell 121.19% to -$9.3 million in Q4 2022 year-over-year; TTM through Dec 2022 was -$20.9 million, a 137.45% decrease, with the full-year FY2025 number at -$6.0 million, down 30.92% from a year prior.
  • Net Cash Flow hit -$9.3 million in Q4 2022 for Cardiol Therapeutics, down from -$1.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $43.8 million in Q4 2021 to a low of -$9.3 million in Q4 2022.